Nancy Y Yu1, Adina Iftimi1, Christina Yau2,3, Nicholas P Tobin4, Laura van 't Veer5, Katherine A Hoadley6, Christopher C Benz3, Bo Nordenskjöld7, Tommy Fornander4, Olle Stål7,8, Kamila Czene9, Laura J Esserman2, Linda S Lindström1. 1. Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden. 2. Department of Surgery, University of California, San Francisco, San Francisco. 3. Buck Institute for Research on Aging, Novato, California. 4. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 5. Department of Laboratory Medicine, University of California, San Francisco, San Francisco. 6. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill. 7. Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. 8. Department of Oncology, Linköping University, Linköping, Sweden. 9. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Abstract
IMPORTANCE: Patients with estrogen receptor (ER)-positive breast cancer have a long-term risk for fatal disease. However, the tumor biological factors that influence the long-term risk and the benefit associated with endocrine therapy are not well understood. OBJECTIVE: To compare the long-term survival from tamoxifen therapy for patients with luminal A or luminal B tumor subtype. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of patients from the Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990, which randomized postmenopausal patients with lymph node-negative breast cancer to receive adjuvant tamoxifen or no endocrine therapy. Tumor tissue sections were assessed in 2014 using immunohistochemistry and Agilent microarrays. Only patients with luminal A or B subtype tumors were evaluated. Complete long-term follow-up data up to the end of the STO-3 trial on December 31, 2012, were obtained from the Swedish National registers. Data analysis for the secondary analysis was conducted in 2017 and 2018. INTERVENTIONS: Patients were randomized to receive at least 2 years of tamoxifen therapy or no endocrine therapy; patients without recurrence who reconsented were further randomized to 3 additional years of tamoxifen therapy or no endocrine therapy. MAIN OUTCOMES AND MEASURES: Distant recurrence-free interval (DRFI) by luminal A and luminal B subtype and trial arm was assessed by Kaplan-Meier analyses and time-dependent flexible parametric models to estimate time-varying hazard ratios (HRs) that were adjusted for patient and tumor characteristics. RESULTS: In the STO-3 treated trial arm, 183 patients had luminal A tumors and 64 patients had luminal B tumors. In the untreated arm, 153 patients had luminal A tumors and 62 had luminal B tumors. Age at diagnosis ranged from 45 to 73 years. A statistically significant difference in DRFI by trial arm was observed (log rank, P < .001 [luminal A subtype, n = 336], P = .04 [luminal B subtype, n = 126]): the 25-year DRFI for luminal A vs luminal B subtypes was 87% (95% CI, 82%-93%) vs 67% (95% CI, 56%-82%) for treated patients, and 70% (95% CI, 62%-79%) vs 54% (95% CI, 42%-70%) for untreated patients, respectively. Patients with luminal A tumors significantly benefited from tamoxifen therapy for 15 years after diagnosis (HR, 0.57; 95% CI, 0.35-0.94), and those with luminal B tumors benefited from tamoxifen therapy for 5 years (HR, 0.38; 95% CI, 0.24-0.59). CONCLUSIONS AND RELEVANCE: Patients with luminal A subtype tumors had a long-term risk of distant metastatic disease, which was reduced by tamoxifen treatment, whereas patients with luminal B tumors had an early risk of distant metastatic disease, and tamoxifen benefit attenuated over time.
IMPORTANCE: Patients with estrogen receptor (ER)-positive breast cancer have a long-term risk for fatal disease. However, the tumor biological factors that influence the long-term risk and the benefit associated with endocrine therapy are not well understood. OBJECTIVE: To compare the long-term survival from tamoxifen therapy for patients with luminal A or luminal B tumor subtype. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of patients from the Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990, which randomized postmenopausal patients with lymph node-negative breast cancer to receive adjuvant tamoxifen or no endocrine therapy. Tumor tissue sections were assessed in 2014 using immunohistochemistry and Agilent microarrays. Only patients with luminal A or B subtype tumors were evaluated. Complete long-term follow-up data up to the end of the STO-3 trial on December 31, 2012, were obtained from the Swedish National registers. Data analysis for the secondary analysis was conducted in 2017 and 2018. INTERVENTIONS: Patients were randomized to receive at least 2 years of tamoxifen therapy or no endocrine therapy; patients without recurrence who reconsented were further randomized to 3 additional years of tamoxifen therapy or no endocrine therapy. MAIN OUTCOMES AND MEASURES: Distant recurrence-free interval (DRFI) by luminal A and luminal B subtype and trial arm was assessed by Kaplan-Meier analyses and time-dependent flexible parametric models to estimate time-varying hazard ratios (HRs) that were adjusted for patient and tumor characteristics. RESULTS: In the STO-3 treated trial arm, 183 patients had luminal A tumors and 64 patients had luminal B tumors. In the untreated arm, 153 patients had luminal A tumors and 62 had luminal B tumors. Age at diagnosis ranged from 45 to 73 years. A statistically significant difference in DRFI by trial arm was observed (log rank, P < .001 [luminal A subtype, n = 336], P = .04 [luminal B subtype, n = 126]): the 25-year DRFI for luminal A vs luminal B subtypes was 87% (95% CI, 82%-93%) vs 67% (95% CI, 56%-82%) for treated patients, and 70% (95% CI, 62%-79%) vs 54% (95% CI, 42%-70%) for untreated patients, respectively. Patients with luminal A tumors significantly benefited from tamoxifen therapy for 15 years after diagnosis (HR, 0.57; 95% CI, 0.35-0.94), and those with luminal B tumors benefited from tamoxifen therapy for 5 years (HR, 0.38; 95% CI, 0.24-0.59). CONCLUSIONS AND RELEVANCE: Patients with luminal A subtype tumors had a long-term risk of distant metastatic disease, which was reduced by tamoxifen treatment, whereas patients with luminal B tumors had an early risk of distant metastatic disease, and tamoxifen benefit attenuated over time.
Authors: Ilana Schlam; Paolo Tarantino; Stefania Morganti; Filipa Lynce; Dario Trapani; Erica L Mayer; Ana C Garrido-Castro; Ada Waks; Sara M Tolaney Journal: Drugs Date: 2022-10-07 Impact factor: 11.431
Authors: Mustapha Abubakar; Maeve Mullooly; Sarah Nyante; Ruth M Pfeiffer; Erin J Aiello Bowles; Renata Cora; Clara Bodelon; Eboneé Butler; Donna Butcher; Lawrence Sternberg; Melissa A Troester; Sheila Weinmann; Mark Sherman; Andrew G Glass; Amy Berrington de Gonzalez; Gretchen L Gierach Journal: JNCI Cancer Spectr Date: 2022-05-02
Authors: Nicole A Traphagen; Sarah R Hosford; Amanda Jiang; Jonathan D Marotti; Brooke L Brauer; Eugene Demidenko; Todd W Miller Journal: Oncogene Date: 2021-04-19 Impact factor: 9.867
Authors: Miguel Quintela-Fandino; Maria J Bueno; Silvana Mouron; Luis Manso; Eduardo Caleiras; Jose L Rodriguez-Peralto; Oscar M Rueda; Carlos Caldas; Ramon Colomer Journal: Breast Cancer Res Date: 2021-02-12 Impact factor: 6.466
Authors: Johanna Holm; Nancy Yiu-Lin Yu; Annelie Johansson; Alexander Ploner; Per Hall; Linda Sofie Lindström; Kamila Czene Journal: JNCI Cancer Spectr Date: 2020-10-07
Authors: Matthew Mills; Casey Liveringhouse; Frank Lee; Ronica H Nanda; Kamran A Ahmed; Iman R Washington; Ram Thapa; Brooke L Fridley; Peter Blumencranz; Martine Extermann; Loretta Loftus; Lodovico Balducci; Roberto Diaz Journal: J Geriatr Oncol Date: 2020-08-26 Impact factor: 3.599
Authors: Nicolai J Toft; Trine V Axelsen; Helene L Pedersen; Marco Mele; Mark Burton; Eva Balling; Tonje Johansen; Mads Thomassen; Peer M Christiansen; Ebbe Boedtkjer Journal: Elife Date: 2021-07-05 Impact factor: 8.140
Authors: Huma Dar; Annelie Johansson; Anna Nordenskjöld; Adina Iftimi; Christina Yau; Gizeh Perez-Tenorio; Christopher Benz; Bo Nordenskjöld; Olle Stål; Laura J Esserman; Tommy Fornander; Linda S Lindström Journal: JAMA Netw Open Date: 2021-06-01